CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

STRIDE and A+B demonstrated superiority vs sorafenib (S) for overall survival (OS), with median follow-up times of 33.2m and 15.6m, respectively. As there are no trials comparing these two regimens, this analysis estimated the comparative efficacy and safety of STRIDE vs A+B, based on the HIMALAYA and IMbrave 150 clinical trials.